Lucentis

also known as Ranibizumab · RBZ

Monoclonal antibody targets VEGFA via inhibition

Regulatory milestones approvals, filings & regulatory actions · 11 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (9)	US (FDA)	LUCENTIS	—	2008-04-23 – 2017-04-15	fda.gov ↗
Approved	EU (EMA)	Lucentis	—	2007-01-22	europa.eu ↗
Approved	US (FDA)	LUCENTIS	—	2006-06-30	fda.gov ↗

Trials 11

today

US approved 2006

EU approved 2007

NCT04667039 · Ph 3 NCT04063358 · Ph 3 NCT03927690 · Ph 2 NCT03097068 · Ph 4 NCT05571267 · Ph 2 NCT02944227 · Ph 4 NCT02543229 · Ph 1 NCT01414153 · Ph 2 NCT01638858 · not/applicable NCT00467935 · Ph 1/2 NCT00457678 · Ph 2

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial · 1 met primary
Phase 1	NCT02543229	Jul 2015 → Feb 2017	age-related macular degeneration, ocular vascular disorder	Opthea Limited	Completed	Met primary
Phase 1/21 trial
Phase 1/2	NCT00467935	Mar → Nov 2007	macular degeneration	Retina Research Foundation	Completed	No outcome recorded
Phase 24 trials · 1 missed
Phase 2	NCT03927690	May 2019 → Jun 2022	diabetic macular edema	Novartis Pharmaceuticals	Completed	Missed primary
Phase 2	NCT05571267	Oct 2016 → Apr 2018	wet macular degeneration	IVERIC bio, Inc.	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01414153	Aug 2012 → May 2015	wet macular degeneration	Lpath, Inc.	Completed	No outcome recorded
Phase 2	NCT00457678	Jan → Dec 2007	age-related macular degeneration	Vitreous -Retina- Macula Consultants of New York	Withdrawn	No outcome recorded Stop: Enrollment
Phase 32 trials
Phase 3	NCT04667039	Mar 2022 → Aug 2024	wet macular degeneration	AO GENERIUM	Unknown	No outcome recorded
Phase 3	NCT04063358	Aug 2019 → Aug 2021	cataract, diabetic macular edema	Second Military Medical University	Unknown	No outcome recorded
Phase 42 trials
Phase 4	NCT03097068	Apr → Dec 2017	diabetic macular edema	Vitreo-Retinal Associates, Michigan	Completed	No outcome recorded
Phase 4	NCT02944227	Mar 2016 → Feb 2017	wet macular degeneration	Seoul National University Hospital	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT01638858	Oct 2011 → Jul 2014	age-related macular degeneration	University of Luebeck	Completed	No outcome recorded
Comparator or background therapy25 trials
Phase 1	NCT04884399 Comparator	Jun 2021 → Dec 2022	wet macular degeneration	Shanghai Biomabs Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03312283 Comparator	Dec 2017 → Apr 2019	wet macular degeneration	Qilu Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02022540 Background	Feb 2014 → Mar 2016	wet macular degeneration	PanOptica, Inc.	Completed	No outcome recorded
Phase 1	NCT02591914 Background	Feb 2014 → May 2016	wet macular degeneration	Retinal Consultants of Arizona	Completed	No outcome recorded
Phase 1/2	NCT02121353 Comparator	Nov 2013 → Jan 2016	age-related macular degeneration	Pfenex, Inc	Completed	No outcome recorded
Phase 2	NCT03362190 Background	Oct 2017 → Oct 2018	wet macular degeneration	Ophthotech Corporation	Completed	No outcome recorded
Phase 2	NCT03211234 Comparator	Jul 2017 → Dec 2019	age-related macular degeneration	Santen Inc.	Completed	No outcome recorded
Phase 2	NCT02397954 Background	Mar → Oct 2015	—	Ophthotech Corporation	Completed	No outcome recorded
Phase 2	NCT02214628 Background	Jul 2014 → Dec 2016	age-related macular degeneration	Ophthotech Corporation	Terminated	No outcome recorded
Phase 2	NCT01089517 Comparator	Mar 2010 → Jun 2012	age-related macular degeneration	Ophthotech Corporation	Completed	No outcome recorded
Phase 2/3	NCT05297292 Comparator	May 2021 → May 2023	wet macular degeneration	Mabwell (Shanghai) Bioscience Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT07515079 Comparator	Oct 2024 → Apr 2027 expected	diabetic macular edema	Bio-Thera Solutions	Recruiting	No outcome recorded
Phase 3	NCT06305416 Comparator	Mar 2024 → Oct 2025 overdue	diabetic macular edema, macular retinal edema	Incepta Pharmaceuticals Ltd	Recruiting	No outcome recorded
Phase 3	NCT05003245 Comparator	Nov 2021 → May 2024	wet macular degeneration	Shanghai Henlius Biotech	Completed	No outcome recorded
Phase 3	NCT04690556 Comparator	Sep 2020 → May 2024	wet macular degeneration	Lupin Ltd.	Completed	Met primary
Phase 3	NCT04857177 Comparator	Oct 2018 → Mar 2021	wet macular degeneration	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 3	NCT03203447 Comparator	Mar → Dec 2018	macular retinal edema, retinal vein occlusion	Clearside Biomedical, Inc.	Terminated	No outcome recorded
Phase 3	NCT02033031 Comparator	Aug → Nov 2012	occlusion of tributary of retinal vein	Medical University of Vienna	Completed	No outcome recorded
Phase 3	NCT01170767 Comparator	Jun 2009 → Dec 2012	age-related macular degeneration	Hospices Civils de Lyon	Completed	Met primary
Phase 4	NCT02684084 Comparator	Nov 2015 → Nov 2016	diabetic macular edema	North Toronto Eye Care Laser and Eye Specialists	Terminated	No outcome recorded
Phase 4	NCT01863199 Comparator	May 2013 → Nov 2015	wet macular degeneration	Retinal Consultants of Arizona	Completed	No outcome recorded
—	NCT01521819 Background	Aug 2012 → Aug 2013	age-related macular degeneration, retinal detachment	Oraya Therapeutics, Inc.	Unknown	No outcome recorded
—	NCT01640171 Background	Jul 2012 → Sep 2013	age-related macular degeneration, central retinal vein occlusion, diabetic macular edema	Retina Vitreous Associates of Florida	Completed	No outcome recorded
—	NCT01473251 Comparator	Nov 2011 → Apr 2014	diabetic macular edema, wet macular degeneration	Vitreo-Retinal Associates, Michigan	Completed	No outcome recorded
—	NCT00455871 Comparator	Apr 2007 → Oct 2010	age-related macular degeneration	Barnes Retina Institute	Unknown	No outcome recorded

Press releases naming this drug 96 releases

Date	Issuer	Release
2026-07-20	Melt Pharmaceuticals	Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 harrow.com ↗
2026-06-05	Lupin Limited	Lupin Receives Approval from U.S. FDA for RanluspecTM (ranibizumab) Injection lupin.com ↗
2026-06-03	Xbrane Biopharma AB	Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) xbrane.com ↗
2026-04-30	Xbrane Biopharma AB	XBRANE SUBMITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA xbrane.com ↗
2025-12-23	Zydus Lifesciences Limited	Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA zyduslife.com ↗
2025-12-23	Formycon AG	FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner formycon.com ↗
2025-12-23	Polpharma Biologics S.A.	Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA polpharmabiologics.com ↗
2025-11-20	Formycon AG	Ranibizumab Biosimilar Epruvy® launched in Germany formycon.com ↗
2025-11-19	Xbrane Biopharma AB	XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA xbrane.com ↗
2025-10-21	Formycon AG	Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe formycon.com ↗
2025-10-21	Polpharma Biologics S.A.	Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar polpharmabiologics.com ↗
2025-10-20	Santen Gmbh	Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea santen.com ↗
2025-10-19	Xbrane Biopharma AB	Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate xbrane.com ↗
2025-07-01	Formycon AG	Bio Usawa becomes partner for the commercialization of FYB201/BioUcenta™ (ranibizumab) across Sub-Saharan Africa formycon.com ↗
2025-06-05	Formycon AG	Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil formycon.com ↗
2025-06-04	Polpharma Biologics S.A.	Lucentis® biosimiliar Ranivisio® (ranibizumab) approved as a new treatment for debilitating retinopathies in Brazil polpharmabiologics.com ↗
2025-05-23	Xbrane Biopharma AB	Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) updates on US FDA BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) xbrane.com ↗
2024-12-31	Xbrane Biopharma AB	XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA xbrane.com ↗
2024-08-05	Lupin Limited	Lupin Announces Successful Completion of Phase 3 Trials for Lucentis® Biosimilar lupin.com ↗
2024-05-10	Xbrane Biopharma AB	Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US xbrane.com ↗
2024-04-11	Formycon AG	Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) formycon.com ↗
2024-03-11	Formycon AG	FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region formycon.com ↗
2024-01-18	Formycon AG	Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023 formycon.com ↗
2023-12-07	Formycon AG	Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis® formycon.com ↗
2023-11-24	Enzene Biosciences Ltd.	Enzene Biosciences launches biosimilar Ranibizumab enzene.com ↗
2023-11-10	Lupin Limited	Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar lupin.com ↗
2023-10-10	Formycon AG	Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States formycon.com ↗
2023-10-04	Coherus Oncology, Inc.	CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch coherus.com ↗
2023-07-25	Xbrane Biopharma AB	STADA and Xbrane weigh options for ranibizumab biosimilar candidate xbrane.com ↗
2023-06-21	Xbrane Biopharma AB	Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate xbrane.com ↗
2023-04-25	Xbrane Biopharma AB	STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract xbrane.com ↗
2023-04-24	Xbrane Biopharma AB	XBRANE submits BLA for ranibizumab biosimilar candidate to FDA xbrane.com ↗
2023-02-13	Coherus Oncology, Inc.	Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services coherus.com ↗
2023-01-17	Xbrane Biopharma AB	STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® xbrane.com ↗
2022-12-15	Xbrane Biopharma AB	XBRANE PROVIDES AN UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE FDA FILING xbrane.com ↗
2022-11-11	Xbrane Biopharma AB	STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® xbrane.com ↗
2022-09-19	Coherus Oncology, Inc.	Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 coherus.com ↗
2022-09-16	Xbrane Biopharma AB	STADA and Xbrane welcome EMA positive opinion for ranibizumab biosimilar candidate Ximluci xbrane.com ↗
2022-09-02	Polpharma Biologics S.A.	European Commission approves FYB201/Ranivisio®1 (Ranivisio – Ranibizumab), a biosimilar to Lucentis®2 polpharmabiologics.com ↗
2022-08-29	Formycon AG	European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2 formycon.com ↗
2022-08-29	Teva Branded Pharmaceutical Products R&D, Inc.	European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries tevapharm.com ↗
2022-08-26	Formycon AG	Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2 formycon.com ↗
2022-08-05	Polpharma Biologics S.A.	U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLI™* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®** polpharmabiologics.com ↗
2022-08-03	Formycon AG	U.S. Food and Drug Administration (FDA) approved FYB201/CIMERLITM1 (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®2 formycon.com ↗
2022-08-03	Formycon AG	Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2 formycon.com ↗
2022-08-02	Coherus Oncology, Inc.	FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity coherus.com ↗
2022-07-04	Xbrane Biopharma AB	Xbrane provides update on ranibizumab biosimilar candidate FDA filing xbrane.com ↗
2022-06-24	Formycon AG	FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA formycon.com ↗
2022-06-02	Biogen	Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States biogen.com ↗
2022-05-30	Xbrane Biopharma AB	Xbrane provides update on ranibizumab biosimilar candidate FDA filing xbrane.com ↗
2022-05-17	Formycon AG	United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis®¹, to be Commercialized by Teva as ONGAVIA® formycon.com ↗
2022-05-17	Formycon AG	FYB201, Formycon's Biosimilar for Lucentis®¹, achieves Marketing Authorization in United Kingdom formycon.com ↗
2022-05-17	Teva Branded Pharmaceutical Products R&D, Inc.	United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼ tevapharm.com ↗
2021-12-14	Polpharma Biologics S.A.	Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered into a commercialization agreement for biosimilar Ranibizumab polpharmabiologics.com ↗
2021-12-14	Polpharma Biologics S.A.	Bioeq, the Polpharma Biologics Group joint venture company and MS Pharma sign exclusive agreement for Ranibizumab in MENA polpharmabiologics.com ↗
2021-10-04	Polpharma Biologics S.A.	Polpharma Biologics Group announces that the Biologics License Application (BLA) submitted by its joint venture Bioeq for its biosimilar Ranibizumab has been accepted for review by the U.S. Food and Drug Administration (FDA) polpharmabiologics.com ↗
2021-10-04	Coherus Oncology, Inc.	Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting coherus.com ↗
2021-10-01	Formycon AG	Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis® (ranibizumab) by the U.S. Food and Drug Administration (FDA) formycon.com ↗
2021-10-01	Coherus Oncology, Inc.	Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review coherus.com ↗
2021-09-30	Xbrane Biopharma AB	Xbrane Biopharma AB announces that partner STADA’s Marketing Authorization Application for ranibizumab is submitted and validated by European Medicines Agency xbrane.com ↗
2021-09-20	Biogen	FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) biogen.com ↗
2021-08-06	Polpharma Biologics S.A.	Polpharma Biologics Group announces that its joint venture Bioeq has submitted a biologics license application (BLA) for biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA) polpharmabiologics.com ↗
2021-08-05	Formycon AG	Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA) formycon.com ↗
2021-06-29	Formycon AG	Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA) formycon.com ↗
2021-06-28	Formycon AG	Teva Pharmaceutical Industries Ltd. becomes strategic partner for the commercialization of FYB201, Formycon's biosimilar candidate to Lucentis(R)1 (ranibizumab) in Europe, Canada, Israel and New Zealand formycon.com ↗
2021-06-25	Biogen	Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™ biogen.com ↗
2021-06-24	Hoffmann-La Roche	FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) roche.com ↗
2021-06-23	Genentech, Inc.	FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD) gene.com ↗
2021-03-01	Formycon AG	Formycon confirms BLA-Submission Strategy and Timeline for its Lucentis(R)* Biosimilar-Candidate FYB201 following consultation with the FDA formycon.com ↗
2020-11-18	Biogen	Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) biogen.com ↗
2020-10-06	Biogen	Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) biogen.com ↗
2020-07-22	Hoffmann-La Roche	Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration roche.com ↗
2020-07-22	Genentech, Inc.	Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration gene.com ↗
2020-05-27	Hoffmann-La Roche	Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration roche.com ↗
2020-05-26	Genentech, Inc.	Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration gene.com ↗
2019-11-06	Coherus Oncology, Inc.	Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States coherus.com ↗
2019-07-26	Novartis Pharmaceuticals	Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness novartis.com ↗
2019-04-04	ThromboGenics	Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for the treatment of DME, ahead of schedule oxurion.com ↗
2018-10-04	Xbrane Biopharma AB	Xbrane Biopharma announces results of in-vivo study showing equivalent tolerability and pharmacokinetic profile of Xlucane compared to Lucentis® xbrane.com ↗
2018-09-22	Novartis Pharmaceuticals	Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness novartis.com ↗
2018-07-25	Genentech, Inc.	Genentech Unveils Positive Phase II Results for the Port Delivery System with Ranibizumab (PDS), the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD) gene.com ↗
2018-05-01	Formycon AG	Formycon and Bioeq Achieve Important Milestone: Biosimilar Ranibizumab Candidate FYB201 Shows Efficacy Comparable to the Reference Product in Phase III Study formycon.com ↗
2018-04-27	BioInvent International AB	BioInvent's collaboration partner ThromboGenics initiates a Phase II combination study with the drug candidate THR-317 and ranibizumab bioinvent.com ↗
2018-04-27	ThromboGenics	ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME oxurion.com ↗
2018-03-21	Genentech, Inc.	FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy gene.com ↗
2018-01-30	Celon Pharma SA	Raport bieżący nr 3/2018 – Podpisanie umowy na rozwój przemysłowy i wytwarzanie do badań klinicznych białka anty-VEGF – leku biopodobnego do Lucentis celonpharma.com ↗
2018-01-30	Celon Pharma SA	Podpisanie umowy na rozwój przemysłowy i wytwarzanie do badań klinicznych białka anty-VEGF – leku biopodobnego do Lucentis celonpharma.com ↗
2017-04-18	Hoffmann-La Roche	FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States roche.com ↗
2017-04-17	Genentech, Inc.	FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States gene.com ↗
2017-01-05	Genentech, Inc.	FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization gene.com ↗
2016-12-07	Novartis Pharmaceuticals	Novartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions novartis.com ↗
2016-10-14	Genentech, Inc.	FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe gene.com ↗
2016-10-10	Genentech, Inc.	FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization gene.com ↗
2016-02-22	Formycon AG	Formycon and bioeq enroll first patient in pivotal phase III study with biosimilar ranibizumab (FYB201) formycon.com ↗
2015-10-06	Formycon AG	Global strategic partners bioeq and Formycon initiate pivotal phase III clinical trial with their Lucentis® biosimilar formycon.com ↗
2015-02-06	Genentech, Inc.	FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Treatment of Diabetic Retinopathy in People with Diabetic Macular Edema gene.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 36 sources stand behind the page.

Field	Value	Cited text
Known as	Lucentis	“A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the...” NCT02214628 ↗ 35 “intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema” NCT01640171 ↗ “Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.” NCT02397954 ↗ NCT00455871 ↗ NCT03203447 ↗ NCT01638858 ↗ NCT00467935 ↗ NCT02033031 ↗ NCT03097068 ↗ NCT05003245 ↗ NCT03312283 ↗ Show 25 more sources
Known as	Ranibizumab	“Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.” NCT04857177 ↗ 5 “Comparing the Efficacy and Safety of BAT5906 Versus Ranibizumab (Lucentis®) in Patients With Diabetic Macular Edema (DME)” NCT07515079 ↗ “Lucentis (Ranibizumab) plus reduced fluence Photodynamic Therapy With Visudyne” NCT00455871 ↗ “Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks” NCT06305416 ↗ “intravitreal injection Lucentis (ranibizumab)” NCT00467935 ↗ “Lucentis (Ranibizumab)” NCT01638858 ↗
Known as	RBZ	“LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME” NCT02684084 ↗
Action	Inhibit	“anti-vascular endothelial growth factor (VEGF) therapy” NCT02397954 ↗
Modality	Monoclonal antibody	“anti-VEGF recombinant humanized monoclonal antibody fragment” NCT05003245 ↗
Route	Intravitreal	“Lucentis intravitreal injection” NCT00455871 ↗
Target	VEGFA	“LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME” NCT02684084 ↗